756 related articles for article (PubMed ID: 18096209)
21. The role of optimal debulking in advanced stage serous carcinoma of the uterus.
Moller KA; Gehrig PA; Van Le L; Secord AA; Schorge J
Gynecol Oncol; 2004 Jul; 94(1):170-4. PubMed ID: 15262137
[TBL] [Abstract][Full Text] [Related]
22. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation.
Jolly S; Vargas CE; Kumar T; Weiner SA; Brabbins DS; Chen PY; Floyd W; Martinez AA
Gynecol Oncol; 2006 Oct; 103(1):87-93. PubMed ID: 16545441
[TBL] [Abstract][Full Text] [Related]
23. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
24. Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide.
Chambers JT; Chambers SK; Kohorn EI; Carcangiu ML; Schwartz PE
Gynecol Oncol; 1996 Mar; 60(3):438-42. PubMed ID: 8774654
[TBL] [Abstract][Full Text] [Related]
25. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma.
Dubernard G; Morice P; Rey A; Camatte S; Fourchotte V; Thoury A; Pomel C; Pautier P; Lhommé C; Duvillard P; Castaigne D
Eur J Surg Oncol; 2004 Nov; 30(9):976-81. PubMed ID: 15498644
[TBL] [Abstract][Full Text] [Related]
26. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
Fader AN; von Gruenigen V; Gibbons H; Abushahin F; Starks D; Markman M; Belinson J; Rose P
Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784
[TBL] [Abstract][Full Text] [Related]
27. Early stage uterine papillary serous carcinoma of the endometrium: effect of adjuvant whole abdominal radiotherapy and pathologic parameters on outcome.
Lim P; Al Kushi A; Gilks B; Wong F; Aquino-Parsons C
Cancer; 2001 Feb; 91(4):752-7. PubMed ID: 11241243
[TBL] [Abstract][Full Text] [Related]
28. Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.
Fader AN; Nagel C; Axtell AE; Zanotti KM; Kelley JL; Moore KN; Secord AA; Walsh CS; Huh WK; Gehrig PA; Gibbons H; Rose PG; Havrilesky LJ; Tuller E; Drake RD; Bottsford-Miller J; O'Malley DM;
Gynecol Oncol; 2009 Mar; 112(3):558-62. PubMed ID: 19118888
[TBL] [Abstract][Full Text] [Related]
29. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma.
Thomas MB; Mariani A; Cliby WA; Keeney GL; Podratz KC; Dowdy SC
Gynecol Oncol; 2007 Nov; 107(2):190-3. PubMed ID: 17825394
[TBL] [Abstract][Full Text] [Related]
30. Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma.
Rauh-Hain JA; Growdon WB; Schorge JO; Goodman AK; Boruta DM; McCann C; Horowitz NS; del Carmen MG
Gynecol Oncol; 2010 Nov; 119(2):299-304. PubMed ID: 20691465
[TBL] [Abstract][Full Text] [Related]
31. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study.
Gadducci A; Landoni F; Sartori E; Maggino T; Zola P; Gabriele A; Rossi R; Cosio S; Fanucchi A; Tisi G
Gynecol Oncol; 2001 May; 81(2):150-9. PubMed ID: 11330942
[TBL] [Abstract][Full Text] [Related]
32. Uterine papillary serous carcinoma: epidemiology, pathogenesis and management.
Fader AN; Boruta D; Olawaiye AB; Gehrig PA
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):21-9. PubMed ID: 19952744
[TBL] [Abstract][Full Text] [Related]
33. Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen.
Lee LJ; Demaria R; Berkowitz R; Matulonis U; Viswanathan AN
Gynecol Oncol; 2014 Jan; 132(1):65-9. PubMed ID: 24211401
[TBL] [Abstract][Full Text] [Related]
34. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.
Gershenson DM; Sun CC; Lu KH; Coleman RL; Sood AK; Malpica A; Deavers MT; Silva EG; Bodurka DC
Obstet Gynecol; 2006 Aug; 108(2):361-8. PubMed ID: 16880307
[TBL] [Abstract][Full Text] [Related]
35. Management of aggressive histologic variants of endometrial carcinoma at the Tom Baker Cancer Centre between 1984 and 1994.
Craighead PS; Sait K; Stuart GC; Arthur K; Nation J; Duggan M; Guo D
Gynecol Oncol; 2000 May; 77(2):248-53. PubMed ID: 10785473
[TBL] [Abstract][Full Text] [Related]
36. Long-term survival in uterine clear cell carcinoma and uterine papillary serous carcinoma.
Lindahl B; Persson J; Ranstam J; Willén R
Anticancer Res; 2010 Sep; 30(9):3727-30. PubMed ID: 20944161
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors and treatment-related outcome in patients with uterine papillary serous carcinoma.
Sagr ER; Denschlag D; Kerim-Dikeni A; Stanimir G; Gitsch G; Gilbert L
Anticancer Res; 2007; 27(2):1213-7. PubMed ID: 17465265
[TBL] [Abstract][Full Text] [Related]
38. Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus.
Hong JC; Foote J; Broadwater G; Gaillard S; Havrilesky LJ; Chino JP
Int J Gynecol Cancer; 2017 May; 27(4):720-729. PubMed ID: 28375927
[TBL] [Abstract][Full Text] [Related]
39. Pathologic stage I-II endometrial carcinoma in the elderly: radiotherapy indications and outcome.
Citron JR; Sutton H; Yamada SD; Mehta N; Mundt AJ
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1432-8. PubMed ID: 15275729
[TBL] [Abstract][Full Text] [Related]
40. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival.
Bristow RE; Zerbe MJ; Rosenshein NB; Grumbine FC; Montz FJ
Gynecol Oncol; 2000 Aug; 78(2):85-91. PubMed ID: 10926785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
